Provectus Biopharmaceuticals Announces Acceptance of PV-10® Melanoma Abstract for Oral Presentation at Melanoma Bridge 2020 KNOXVILLE, TN, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from the Company's ongoing Phase 1b/2 study of autolytic cancer immunotherapy PV-10, an injectable...

Data Published In AACR Journal Suggest Biodesix® Test in Development May Identify Melanoma Patients Who Could Benefit from Checkpoint Inhibitors BOULDER, Colo., Dec. 20, 2017 (GLOBE NEWSWIRE) -- Findings published in the American Association for Cancer Research (AACR) peer-reviewed journal Cancer Immunology Research demonstrate that a test...